Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
- Badari Andukuri
- Feb 10
- 9 min read
TOP PHARMACEUTICAL COMPANIES BY REVENUES 2025 (Source: Official websites of pharmaceutical companies)
Rank | Company | Q1 | H1 | 9M | Annual |
1 | Johnson & Johnson | $21.9 | $45.6 | $69.6 | $94.2 |
2 | Roche | $18.7 | $38.3 | $56.8 | $79.3 |
3 | Lilly | $12.7 | $28.3 | $45.9 | $65.2 |
4 | Pfizer | $13.7 | $28.4 | $45.0 | $62.6 |
5 | AbbVie | $13.3 | $28.7 | $44.5 | $61.2 |
6 | AstraZeneca | $12.9 | $28.0 | $43.2 | $58.7 |
7 | Merck | $13.6 | $27.7 | $43.3 | $58.1 |
8 | Novartis | $13.2 | $27.3 | $41.2 | $54.5 |
9 | Sanofi | $11.2 | $23.0 | $37.5 | $51.6 |
10 | Novo Nordisk | $12.2 | $24.2 | $35.7 | $49.0 |
Top 10 pharmaceutical companies by revenues | 2025
JOHNSON AND JOHNSON
Q1 REVENUES: In the first quarter of 2025, Johnson & Johnson reported revenues of $21.9 billion. The Innovative Medicine segment delivered good performance, achieving 4.2% year-over-year growth. This was primarily driven by continued strength in Oncology, led by Darzalex, Carvykti, Erleada, and Rybrevant; robust demand for Tremfya and Simponi in Immunology; and sustained momentum from Spravato in Neuroscience.
Q2 REVENUES: Johnson & Johnson reported second-quarter 2025 sales of $23.7 billion, reflecting a 5.8% year-over-year increase. Total revenues for the first half of 2025 reached $45.6 billion, with pharmaceutical sales accounting for $29.1 billion. Key growth drivers included Darzalex ($6.8 billion), Stelara ($3.3 billion), and Tremfya ($2.1 billion).
Also read: FDA says no to AstraZeneca’s Saphnelo Subcutaneous Formulation for Lupus Patients
Q3 REVENUES: Johnson & Johnson reported third-quarter sales of $24 billion, marking a 6.8% increase year-over-year. Worldwide Innovative Medicine sales hit $15.6 billion, up 6.8%. MedTech sales reached $8.4 billion with a 6.8% increase. Oncology and Neuroscience drove operational gains, even as Stelara's decline due to biosimilar competition and regulatory changes tempered overall figures. Immunology and Neuroscience segments remained resilient, boosted by products like Darzalex, Erleada, Tecvayli, Talvey, Rybrevant, and Caplyta.
The total revenues in the first nine months $69.6 billion.
Q4 REVENUES: Johnson & Johnson reported a strong finish to 2025, with fourth‑quarter revenue climbing 9.1% year over year to 24.6 billion dollars. On an operational basis, sales advanced 7.1%, while adjusted operational growth came in at 6.1%, reflecting underlying demand across the portfolio despite currency and other external headwinds.
For the full year 2025, Johnson & Johnson generated $94.2 billion in reported sales, representing 6.0% growth versus 2024. Operational sales increased 5.3%, and adjusted operational growth was 4.2%, underscoring consistent performance across the company’s pharmaceutical and medtech businesses.
Also read: CDSCO Clears Durvalumab with FLOT as New Perioperative Standard for Gastric Cancer Patients in India
Best selling drugs of Johnson and Johnson
ROCHE
Q1 REVENUES: In the first quarter of 2025, Roche reported revenues of $18.7 billion, reflecting 6% sales growth year-over-year. The Pharmaceuticals Division led performance with an 8% increase, driven by continued strong demand for key therapies. Ocrevus remained the top revenue contributor with $2.2 billion in sales, followed by Hemlibra at $1.4 billion and Vabysmo at $1.2 billion.
Q2 REVENUES: Roche posted a 7% increase in group sales for the first half of 2025, with the pharmaceuticals Division reporting a strong 10% growth. The revenues for the first half of 2025 were $38.3 billion. Leading products included Ocrevus ($4.3 billion), Hemlibra ($3.0 billion), and Vabysmo ($2.5 billion).
Also read: AHA Urges HRSA to Block Eli Lilly’s Expanded 340B Claims-Data Policy; Lilly Hits Back
Q3 REVENUES: Roche reported revenues of approximately $56.8 billion in the first nine months, reflecting a 7% increase in total sales at constant exchange rates and a 2% rise in Swiss francs (CHF).
The Pharmaceuticals Division recorded 9% growth at constant exchange rates and 4% in CHF, driven by sustained demand for its key therapies addressing serious medical conditions. Major growth drivers included Phesgo for breast cancer, Xolair for food allergies, Hemlibra for haemophilia A, Vabysmo for significant eye diseases, and Ocrevus for multiple sclerosis.
During the first nine months of the year, leading products by sales were Ocrevus (CHF 5.2 billion), Hemlibra (CHF 3.5 billion), and Vabysmo (CHF 3.0 billion).
Q4 REVENUES: Roche announced a 7% year-on-year growth in group sales at constant exchange rates (2% in Swiss francs) for 2025, reflecting broad-based strength across its Pharmaceuticals and Diagnostics divisions. The company also reported an 8% surge in fourth-quarter sales, sustaining its positive momentum through the end of the year.
Pharmaceuticals Division : The pharmaceuticals segment achieved a 9% increase in sales (3% in CHF), driven by expanded patient access and continued uptake of key therapies. The strongest contributors included Phesgo for breast cancer, Xolair in food allergy management, Ocrevus for multiple sclerosis, Hemlibra for haemophilia A, and Vabysmo for retinal diseases.
Diagnostics Division: The Diagnostics business recorded a 2% revenue increase (-3% in CHF).
Best selling drugs of Roche
LILLY
Q3 REVENUES: Eli Lilly reported a strong third-quarter 2025 revenue of $17.6 billion, representing a 54% increase year-over-year, led by demand for its weight-loss and diabetes therapies Mounjaro and Zepbound.
The company’s revenues for the first nine months stood at $45.9 billion, reflecting sustained growth momentum across its portfolio. Key growth drivers in the first six months included $15.5 billion in revenue from Mounjaro and $9.2 billion from Zepbound, underscoring their blockbuster status in the GLP-1 drug market.
Total year revenues: Eli Lilly reported a sharp increase in fourth‑quarter 2025 revenue, which rose 43 percent year over year to 19.3 billion dollars, largely reflecting strong volume gains from Mounjaro and Zepbound.
For the full year 2025, the company generated 65.2 billion dollars in revenue, representing a 45 percent increase compared with 2024 as incretin‑based therapies continued to drive exceptional growth.
Best selling drugs of Eli Lilly
Sl No | Brand | Revenues |
1 | Mounjaro | $23.0 billion |
2 | Zepbound | $13.5 billion |
3 | Verzenio | $5.7 billion |
4 | Taltz | $3.6 billion |
PFIZER
Q1 REVENUES: Pfizer reported first-quarter 2025 revenues of $13.7 billion, representing a decline of $1.2 billion, or 8%, compared to the same period in the prior year. Despite the overall decrease, key products continued to perform strongly, with Eliquis generating $1.9 billion in revenue, the Prevnar family contributing $1.7 billion, and the Vyndaqel family reaching $1.5 billion.
Q3 REVENUES: Pfizer reported third-quarter 2025 revenues of $16.7 billion, representing a 7% operational decline compared to the same period last year.
For the first nine months of 2025, Pfizer achieved total revenues of $45.0 billion. Major revenue contributors included the Eliquis portfolio with $5.9 billion in sales, the Prevnar vaccine family generating $4.8 billion, and Ibrance contributing $3.0 billion.
ABBVIE
Q1 REVENUES: AbbVie delivered first-quarter 2025 net revenues of $13.343 billion, reflecting an 8.4% increase on a reported basis. The company’s global immunology portfolio generated $6.264 billion in revenue, up 16.6% year-over-year. Growth was led by Skyrizi, which reported $3.4 billion in sales, and Rinvoq, which contributed $1.7 billion.
Q2 REVENUES: AbbVie reported total revenues of $28.8 billion for the first half of 2025. The company’s top-performing products included Skyrizi ($7.8 billion), Rinvoq ($3.7 billion), and Humira ($2.3 billion).
Also read: SFDA approved the registration of Anktiva for selected bladder and lung cancer indications
Q3 REVENUES: AbbVie reported total net revenues of nearly $15.8 billion for the third quarter of 2025, representing a 9.1% increase on a reported basis and 8.4% growth operationally.
In the third quarter, the Immunology Portfolio generated $7.885 billion in global net revenues, with Skyrizi contributing $4.708 billion, Rinvoq $2.184 billion, and Humira $993 million.
The Oncology Portfolio totaled $1.682 billion, slightly down 0.3% reported and 1.3% operationally, including Imbruvica ($706 million), Venclexta ($726 million), and Elahere ($170 million).
The total revenues were $44.5 billion for the first nine months of 2025.
Full year revenues: AbbVie reported 2025 net revenues of $61.2 billion, up about 8.6% on a reported basis and 8.5% operationally.
Immunology brought in $30.4 billion (Skyrizi $17.6B, Rinvoq $8.3B, Humira $4.5B), while Neuroscience reached $10.8 billion. Oncology generated $6.7 billion, and Aesthetics totaled $4.9 billion.
Best selling drugs of AbbVie
Sl No | Brand | Revenues |
1 | Skyrizi | $ 17.6 billion |
2 | Rinvoq | $ 8.3 billion |
3 | Humira | $ 4.5 billion |
4 | Vraylar | $ 3.6 billion |
5 | Imbruvica | $2.9 billion |
ASTRAZENECA
H1 REVENUES: AstraZeneca achieved total revenues of $28.0 billion for the first half of 2025. The company’s top revenue generators included Tagrisso ($3.5 billion), Imfinzi ($2.7 billion), Farxiga ($4.2 billion), and Symbicort ($1.4 billion).
Also read: FDA clears one‑minute subcutaneous mosunetuzumab for heavily pretreated follicular lymphoma
9M REVENUES: AstraZeneca reported total revenues of $43.2 billion for the first nine months of the year, including $15.2 billion in the third quarter. Key growth drivers included Tagrisso with $5.2 billion in revenues, Imfinzi with $4.3 billion, and Farxiga with $6.3 billion.
Full year revenues: AstraZeneca reported total revenues of $58.7 billion, reflecting an 8% year-on-year increase to $58,739 million. This growth was primarily fueled by strong performances in the Oncology, Cardiovascular, Renal & Metabolism (CVRM), Respiratory & Immunology (R&I), and Rare Disease segments. Revenue expansion was observed across all major global markets, while core operating profit experienced a 9% rise.
Sl No | Brand | Revenues |
1 | Farxiga | $ 8.4 billion |
2 | Tagrisso | $ 7.2 billion |
3 | Imfinzi | $ 6.0 billion |
MERCK
Q1 REVENUES: In the first quarter of 2025, Merck reported pharmaceutical revenues of $13.6 billion. The decline was primarily driven by lower sales in vaccines, virology, and immunology. This was partially offset by continued growth in oncology, cardiology, and diabetes.
Keytruda remained the company’s leading product with $7.2 billion in revenue, while Gardasil/Gardasil 9 contributed $1.3 billion.
Q4 REVENUES: Merck announced that its revenue for the fourth quarter reached $14.8 billion, reflecting strong performance in its oncology, cardiometabolic, and respiratory portfolios.
For the full year, the company posted total revenue of $58.1 billion, underscoring continued momentum across key product franchises.
Keytruda (pembrolizumab) generated $31.6 billion in global sales during the year. The increase was driven by significant demand across early-stage cancer indications, including triple-negative breast cancer, non-small cell lung cancer, renal cell carcinoma, cervical cancer, and head and neck malignancies. Sales of KEYTRUDA QLEX totaled $35 million.
Best selling drugs of Merck
NOVARTIS
Q1 REVENUES: In the first quarter of 2025, Novartis reported net sales of $13.2 billion, representing 12% growth year-over-year. Volume contributed 15 percentage points to this growth, underscoring strong underlying demand across key therapies. Leading the performance were Entresto with $2.2 billion in sales and Cosentyx with $1.5 billion.
Q2 REVENUES: Novartis reported net sales of $27.3 billion for the first half of 2025, reflecting an 11% year-over-year increase. Leading contributors to this performance included Entresto ($4.6 billion), Cosentyx ($3.2 billion), and Kisqali ($2.1 billion).
Also read: China Approves Myqorzo and Redemplo, Expanding Options in Hypertrophic Cardiomyopathy and Familial Chylomicronaemia Syndrome
Q3 REVENUES: Novartis reported performance for the first nine months of 2025, with total revenues reaching $41.2 billion, including $13.9 billion in the third quarter.
Entresto led with $6.5 billion in sales, Cosentyx generated $4.9 billion, while Kisqali delivered $3.5 billion reflecting expanding use in breast cancer. Kesimpta contributed $3.2 billion, highlighting sustained adoption in multiple sclerosis.
Full year: Novartis reported full-year 2025 net sales of USD 54.5 billion, with volume growth offset by headwinds from generics and pricing pressure. Generic erosion reduced growth by 6 percentage point.
In the fourth quarter of 2025, Novartis generated USD 13.3 billion in net sales, reflecting resilient performance despite continued impact from US generic competition and pricing adjustments.
Best selling drugs of Novartis
Sl No | Brand | Revenues |
1 | Entresto | $ 7.7 billion |
2 | Cosentyx | $ 6.7 billion |
3 | Kisqali | $ 4.8 billion |
4 | Kesimpta | $ 4.4 billion |
SANOFI
H1 REVENUES: Sanofi reported revenues of $22.8 billion for the first half of 2025, with Dupixent continuing to lead the portfolio, generating $8.5 billion in sales.
Complete year revenues: Sanofi reported annual revenues of $51.6 billion, up 6.2% versus the prior year, driven by strong performance across its portfolio.
Dupixent (dupilumab) delivered $18.5 billion in sales, with continued expansion in key indications:
Approval in Japan for pediatric asthma (December)
U.S. regulatory acceptance for AFRS (November), potentially the 9th indication
EU approval for chronic spontaneous urticaria (CSU) (November)
Best seling drugs of Sanofi
Sl No | Brand | Revenues |
1 | Dupixent | $18.5 billion |
NOVO NORDISK
H1 REVENUES: Novo Nordisk reported revenues of $24.2 billion (DKK 154.9 billion) for the first half of 2025, marking a 16% increase in Danish kroner and 18% growth at constant exchange rates. Leading the company’s performance were Ozempic with $10 billion in sales and Wegovy with $5.7 billion.
Also read: Lilly’s Sofetabart Mipitecan Wins FDA Breakthrough Tag in Tough‑to‑Treat Ovarian Cancer
Complete year revenues: Novo Nordisk reported annual revenues of $49.0 billion (DKK 309 billion) for the year.
The company’s operating profit declined by 1% in Danish kroner but rose 6% at constant exchange rates (CER), reaching DKK 127.7 billion. The underlying performance reflects strong sales growth in core products, partly offset by higher costs and currency effects.
Best selling drugs of Novo Nordisk
Sl No | Brand | Revenues |
1 | Ozempic | $20 billion |
2 | Wegovy | $12.5 billion |
3 | Insulins | $8.4 billion |
Bristol Myers Squibb (BMS)
Bristol Myers Squibb announced that revenue for the fourth quarter of 2025 was approximately 12.5 billion dollars, an increase of 1 percent versus the prior‑year period, with full‑year 2025 revenue totalling 48.2 billion dollars.
Total company revenue of 48.2 billion dollars for the full year was essentially unchanged compared with 2024 on a reported basis and declined 1 percent at constant exchange rates. U.S. revenue for the year was 33.3 billion dollars, while revenue from markets outside the United States reached 14.9 billion dollars.
Best selling drugs of BMS
Sl No | Brand | Revenues |
1 | Eliquis | $14.4 billion |
2 | Opdivo | $10.0 billion |
3 | Orencia | $3.7 billion |
4 | Yervoy | $2.9 billion |